Medigen Vaccine Biologics Corporation (TPEX: 6547)
Taiwan
· Delayed Price · Currency is TWD 48.00
+0.90 (1.91%)
Sep 10, 2024, 1:30 PM CST
Medigen Vaccine Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -694.03 | -1,160 | -1,475 | 1,410 | -674.28 | -617.72 | Upgrade
|
| Depreciation & Amortization | 131.81 | 130 | 127.26 | 112.33 | 122.21 | 118.29 | Upgrade
|
| Other Amortization | 1.5 | 1.17 | 0.63 | 0.22 | 0.04 | 0.2 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | - | - | - | -19.73 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 4.88 | 9.64 | 16.55 | 0.07 | 0.06 | -0.24 | Upgrade
|
| Stock-Based Compensation | 3.03 | 18.31 | 75.61 | 68.82 | 44.66 | 28.93 | Upgrade
|
| Other Operating Activities | 54.49 | -12.44 | 19.32 | -0.02 | -2.87 | 5.05 | Upgrade
|
| Change in Accounts Receivable | -189.35 | 45.29 | 445.79 | -635.73 | -4.46 | - | Upgrade
|
| Change in Inventory | 408.6 | 161.15 | 18.71 | -486.06 | -69.04 | 1.78 | Upgrade
|
| Change in Accounts Payable | -5.63 | -82.64 | 21.72 | 65.63 | 19.28 | -2.41 | Upgrade
|
| Change in Unearned Revenue | - | - | -111.41 | 111.41 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 79.33 | 411.02 | -353.41 | -67.03 | -5.84 | 53.76 | Upgrade
|
| Operating Cash Flow | -205.37 | -478.34 | -1,214 | 579.89 | -589.97 | -462.65 | Upgrade
|
| Capital Expenditures | -34.89 | -38.69 | -139.17 | -133.63 | -99.25 | -7.21 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.17 | - | - | 120 | 29.69 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.89 | -2.27 | -1.17 | -1.34 | -6.05 | -0.08 | Upgrade
|
| Investment in Securities | 2,340 | 636.38 | -2,279 | -881.8 | - | 499.8 | Upgrade
|
| Other Investing Activities | 3.43 | 74.4 | 134.74 | -33.93 | -0.69 | -0.96 | Upgrade
|
| Investing Cash Flow | 2,308 | 669.83 | -2,285 | -930.69 | -76.3 | 381.47 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 30 | 30 | 30 | Upgrade
|
| Long-Term Debt Issued | - | - | 1,755 | - | - | - | Upgrade
|
| Total Debt Issued | - | - | 1,755 | 30 | 30 | 30 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -30 | -60 | -10 | Upgrade
|
| Long-Term Debt Repaid | - | -11.78 | -11.56 | -1.93 | -441.76 | -88.78 | Upgrade
|
| Total Debt Repaid | -1,739 | -11.78 | -11.56 | -31.93 | -501.76 | -98.78 | Upgrade
|
| Net Debt Issued (Repaid) | -1,739 | -11.78 | 1,744 | -1.93 | -471.76 | -68.78 | Upgrade
|
| Issuance of Common Stock | 7.6 | 13.37 | 1,579 | 55.68 | 2,404 | 343.64 | Upgrade
|
| Other Financing Activities | - | - | - | -2.58 | 2.58 | - | Upgrade
|
| Financing Cash Flow | -1,731 | 1.59 | 3,323 | 51.18 | 1,935 | 274.86 | Upgrade
|
| Foreign Exchange Rate Adjustments | -4.08 | -4.22 | 0.35 | -0.11 | -0.22 | -0.13 | Upgrade
|
| Net Cash Flow | 367.79 | 188.87 | -175.44 | -299.73 | 1,269 | 193.54 | Upgrade
|
| Free Cash Flow | -240.26 | -517.02 | -1,353 | 446.26 | -689.22 | -469.86 | Upgrade
|
| Free Cash Flow Margin | -38.54% | -132.70% | -370.64% | 13.60% | -5989.55% | -41951.34% | Upgrade
|
| Free Cash Flow Per Share | -0.73 | -1.57 | -4.18 | 1.39 | -2.49 | -2.03 | Upgrade
|
| Cash Interest Paid | 7.27 | 7.32 | 7.53 | 6.02 | 16.42 | 19.13 | Upgrade
|
| Levered Free Cash Flow | -90.48 | -164.31 | -744.24 | -288.35 | -601.43 | -186.46 | Upgrade
|
| Unlevered Free Cash Flow | -69.51 | -140.83 | -727.43 | -284.59 | -591.17 | -174.5 | Upgrade
|
| Change in Net Working Capital | -293.78 | -509.29 | -169.58 | 933.32 | 175.35 | -62.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.